A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Trial Profile

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Selinexor (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms BOSTON
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 07 Jun 2017 According to a Karyopharm Therapeutics media release, study is supported by robust clinical data from the STOMP study (CTP700253337).
    • 07 Jun 2017 According to a Karyopharm Therapeutics media release, data from this study will be used to support an NDA filing for selinexor for the treatment of relapsed or refractory myeloma.
    • 07 Jun 2017 According to a Karyopharm Therapeutics media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top